{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T18:40:01Z","timestamp":1756665601456,"version":"3.44.0"},"reference-count":14,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2023,4,28]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ivacaftor approval was extended to people with cystic fibrosis (CF) and an <jats:italic>R117H<\/jats:italic> variant in 2014 in the USA. This observational, real-world, postapproval study evaluated long-term outcomes among people with CF and an <jats:italic>R117H<\/jats:italic> variant on ivacaftor using data from the US Cystic Fibrosis Foundation Patient Registry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Key outcomes were evaluated in ivacaftor-treated people with CF and an <jats:italic>R117H<\/jats:italic> variant for up to 36 months before and after treatment initiation using within-group comparisons. Analyses were descriptive in nature, focused on evaluation of observed outcome patterns over time and were performed both overall and for age groups \u22652\u2009to &lt;6 years, \u22656\u2009to &lt;18 years and \u226518 years. Key outcomes included lung function, body mass index (BMI), pulmonary exacerbations (PEx) and hospitalisations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The ivacaftor cohort included 369 people with CF and an <jats:italic>R117H<\/jats:italic> variant who initiated therapy between 1 January 2015 and 31 December 2016. During each of the 12-month intervals following treatment initiation, the mean observed percent predicted forced expiratory volume in 1\u2009s (ppFEV<jats:sub>1<\/jats:sub>) and BMI values were higher and the mean annualised number of PEx and hospitalisation events were lower than pretreatment values. Mean change in ppFEV<jats:sub>1<\/jats:sub> from pretreatment baseline was an increase of 1.5 (95% CI 0.8 to 2.3), 1.7 (95% CI 0.7 to 2.7) and 1.8 (95% CI 0.6 to 3.0) percentage points in the first, second and third years of treatment, respectively. Similar trends were observed in adult and paediatric subgroups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results support the clinical effectiveness of ivacaftor in people with CF and an <jats:italic>R117H<\/jats:italic> variant, including adult and paediatric subgroups.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2022-001447","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T13:22:04Z","timestamp":1685020924000},"page":"e001447","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Registry-based study in people with cystic fibrosis and an <i>R117H<\/i> variant treated with ivacaftor"],"prefix":"10.1136","volume":"10","author":[{"given":"Mark","family":"Higgins","sequence":"first","affiliation":[{"name":"Vertex Pharmaceuticals Europe Ltd, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thalia","family":"Farietta","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Campbell","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josh","family":"Ostrenga","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Foundation, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Elbert","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Foundation, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Shih","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataliya","family":"Volkova","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"2025083111235580000_10.1.e001447.1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcf.2016.11.002","article-title":"Environmental scan of cystic fibrosis research worldwide","volume":"16","author":"Kelly","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2025083111235580000_10.1.e001447.2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025083111235580000_10.1.e001447.3","unstructured":"Cystic Fibrosis Foundation . 2019 Patient Registry: Annual Data Report. 2020. Available: https:\/\/www.cff.org\/Research\/Researcher-Resources\/Patient-Registry\/2019-Patient-Registry-Annual-Data-Report.pdf [Accessed 30 Sep 2021]."},{"key":"2025083111235580000_10.1.e001447.4","unstructured":"Vertex Pharmaceuticals Incorporated . Kalydeco Pi. 2020. Available: https:\/\/www.drugs.com\/pro\/kalydeco.html [Accessed 17 Dec 2020]."},{"key":"2025083111235580000_10.1.e001447.5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jcf.2017.10.003","article-title":"Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation","volume":"17","author":"Wagener","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2025083111235580000_10.1.e001447.6","unstructured":"Cystic Fibrosis Foundation . 2015 Patient Registry: Annual Data Report. 2016. Available: https:\/\/www.cff.org\/our-research\/cf-patient-registry\/2015-patient-registry-annual-data-report.pdf [Accessed Nov 2021]."},{"key":"2025083111235580000_10.1.e001447.7","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201511-781OC"},{"key":"2025083111235580000_10.1.e001447.8","unstructured":"Centers for Disease Control and Prevention . CDC Growth Charts. 2016. Available: https:\/\/www.cdc.gov\/growthcharts\/cdc_charts.htm [Accessed 12 Jan 2022]."},{"key":"2025083111235580000_10.1.e001447.9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2025083111235580000_10.1.e001447.10","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210394"},{"key":"2025083111235580000_10.1.e001447.11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s41030-020-00115-8","article-title":"Real-world outcomes among patients with cystic fibrosis treated with ivacaftor: 2012\u20132016 experience","volume":"6","author":"Higgins","year":"2020","journal-title":"Pulm Ther"},{"key":"2025083111235580000_10.1.e001447.12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s41030-021-00158-5","article-title":"Real-world long-term ivacaftor for cystic fibrosis in France: clinical effectiveness and healthcare resource utilization","volume":"7","author":"Hubert","year":"2021","journal-title":"Pulm Ther"},{"key":"2025083111235580000_10.1.e001447.13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025083111235580000_10.1.e001447.14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial","volume":"3","author":"Moss","year":"2015","journal-title":"Lancet Respir Med"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2022-001447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T18:24:05Z","timestamp":1756664645000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2022-001447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,5,25]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/bmjresp-2022-001447"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2022-001447","relation":{},"ISSN":["2052-4439"],"issn-type":[{"type":"electronic","value":"2052-4439"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}